CL2020000221A1 - Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. - Google Patents

Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.

Info

Publication number
CL2020000221A1
CL2020000221A1 CL2020000221A CL2020000221A CL2020000221A1 CL 2020000221 A1 CL2020000221 A1 CL 2020000221A1 CL 2020000221 A CL2020000221 A CL 2020000221A CL 2020000221 A CL2020000221 A CL 2020000221A CL 2020000221 A1 CL2020000221 A1 CL 2020000221A1
Authority
CL
Chile
Prior art keywords
compositions
treatment
amino acids
diseases related
mitochondrial dysfunction
Prior art date
Application number
CL2020000221A
Other languages
English (en)
Inventor
Paolo Luca Maria Giorgetti
Original Assignee
Professional Dietetics Int Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Professional Dietetics Int Srl filed Critical Professional Dietetics Int Srl
Publication of CL2020000221A1 publication Critical patent/CL2020000221A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSICIÓN PARA PROMOVER LA BIOGÉNESIS MITOCONDRIAL Y MEJORAR LA FUNCIÓN MITOCONDRIAL EN UN SUJETO, LA COMPOSICIÓN COMPRENDE UN AGENTE ACTIVO, DICHO AGENTE ACTIVO QUE CONTIENE LOS AMINOÁCIDOS LEUCINA, ISOLEUCINA, VALINA, TREONINA, LISINA Y ÁCIDO CÍTRICO, ÁCIDO SUCCÍNICO, ÁCIDO MÁLICO.
CL2020000221A 2017-07-28 2020-01-27 Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. CL2020000221A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102017000087376A IT201700087376A1 (it) 2017-07-28 2017-07-28 Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale

Publications (1)

Publication Number Publication Date
CL2020000221A1 true CL2020000221A1 (es) 2020-07-31

Family

ID=60628071

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000221A CL2020000221A1 (es) 2017-07-28 2020-01-27 Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.

Country Status (22)

Country Link
US (1) US11452702B2 (es)
EP (1) EP3658133B1 (es)
JP (1) JP7244184B2 (es)
KR (1) KR102602041B1 (es)
CN (1) CN110996936A (es)
AU (1) AU2018307712B2 (es)
BR (1) BR112020001480A2 (es)
CA (1) CA3070199A1 (es)
CL (1) CL2020000221A1 (es)
DK (1) DK3658133T3 (es)
ES (1) ES2921908T3 (es)
HU (1) HUE059500T2 (es)
IT (1) IT201700087376A1 (es)
LT (1) LT3658133T (es)
MX (1) MX395112B (es)
MY (1) MY200739A (es)
PH (1) PH12020500189A1 (es)
PL (1) PL3658133T3 (es)
PT (1) PT3658133T (es)
RS (1) RS63392B1 (es)
SG (1) SG11201912098SA (es)
WO (1) WO2019021137A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700087359A1 (it) * 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
IT201800006725A1 (it) 2018-06-27 2019-12-27 Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche
IT201900002109A1 (it) * 2019-02-13 2020-08-13 Professional Dietetics Spa Composizioni comprendenti amminoacidi per l'uso nel trattamento di lesioni del sistema nervoso centrale
IT202000000454A1 (it) 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per la prevenzione e il trattamento del cancro
IT202000000442A1 (it) 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
ITTO20010804A1 (it) 2001-08-08 2003-02-08 Professional Dietetics Srl Composizioni a base di aminoacidi, idonee alla terapia per la cicatrizzazione e/o riparazione di ferite e lesioni, in particolare per l'appl
ITTO20030789A1 (it) 2003-10-07 2005-04-08 Professional Dietetics Srl Composizione a base di amino acidi per il trattamento
PL2723198T3 (pl) * 2011-06-23 2018-01-31 Innova Food Ab Ulepszona kompozycja spożywcza
US9198454B2 (en) * 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
US9597367B2 (en) * 2013-04-19 2017-03-21 Bioventures, Llc Methods for improving muscle and heart function
ES2651903T3 (es) * 2014-10-08 2018-01-30 Professional Dietetics S.P.A. Composiciones que comprenden aminoácidos para su uso en el tratamiento del estado inflamatorio sistémico asociado con el accidente cerebrovascular en pacientes con disfagia
US10226441B2 (en) 2014-12-09 2019-03-12 Nihon Sizen Hakkoh Co., Ltd. Aging inhibitor
MX357998B (es) 2015-03-20 2018-07-11 Antonio Hernandez Miramontes Jorge Una mezcla de acidos carboxilicos, especificamente acido citrico, acido succinico, acido fumarico y acido malico para el tratamiento de pacientes con insuficiencia renal cronica, insuficiencia renal aguda, hepatopatias agudas o cronicas que cursen con hiperamonemia, enfermedades congenitas con alteraciones enzimaticas en el ciclo de la urea, asi como condiciones clínicas que cursen con balance nitrogenado negativo.
CN107708683A (zh) * 2015-05-11 2018-02-16 纽卡斯尔创新有限公司 氨基酸补充
CA2981757C (en) 2015-05-14 2023-06-27 Professional Dietetics S.P.A. Compositions comprising amino acids for use in the treatment of mucositides in neoplasia patients undergoing radiation therapy and/or chemotherapy
WO2017020121A1 (en) * 2015-07-31 2017-02-09 Val-Chum, Limited Partnership Glycerol-3-phosphate phosphatase activators
RU2741637C2 (ru) * 2015-11-27 2021-01-28 Даблгуд Аб Пищевая добавка и композиция для лечения метаболического синдрома
CN105851758A (zh) * 2016-05-18 2016-08-17 何凤祥 氨基酸饮品
IT201700087359A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
IT201800006725A1 (it) 2018-06-27 2019-12-27 Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche

Also Published As

Publication number Publication date
SG11201912098SA (en) 2020-01-30
CA3070199A1 (en) 2019-01-31
HUE059500T2 (hu) 2022-11-28
PH12020500189A1 (en) 2020-09-14
CN110996936A (zh) 2020-04-10
RS63392B1 (sr) 2022-08-31
PL3658133T3 (pl) 2022-07-25
RU2019141226A (ru) 2021-08-30
US20200253906A1 (en) 2020-08-13
JP2020528402A (ja) 2020-09-24
AU2018307712B2 (en) 2023-11-09
MY200739A (en) 2024-01-13
EP3658133B1 (en) 2022-04-06
KR20200033873A (ko) 2020-03-30
MX2020001084A (es) 2022-08-26
AU2018307712A1 (en) 2020-02-13
ES2921908T3 (es) 2022-09-02
US11452702B2 (en) 2022-09-27
JP7244184B2 (ja) 2023-03-22
BR112020001480A2 (pt) 2020-09-08
DK3658133T3 (da) 2022-07-04
MX395112B (es) 2025-03-12
PT3658133T (pt) 2022-07-08
EP3658133A1 (en) 2020-06-03
WO2019021137A1 (en) 2019-01-31
LT3658133T (lt) 2022-08-10
KR102602041B1 (ko) 2023-11-14
NZ761076A (en) 2025-02-28
RU2019141226A3 (es) 2021-10-07
IT201700087376A1 (it) 2019-01-28

Similar Documents

Publication Publication Date Title
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CO2017001994A2 (es) Compuestos activos hacia bromodominios
MX2018012486A (es) Composiciones para aplicacion topica de compuestos.
GT201400043A (es) Imidazopiridazinas sustituidas con amino
MX2018012390A (es) Composiciones de disulfuro de selenio para usarse en el tratamiento de la disfuncion de las glandulas de meibomio.
CL2015002433A1 (es) Imidazopiridazinas sustituidas
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CL2020000551A1 (es) Formulación de uso tópico para el control y la prevención de parásitos en animales.
MX2018007871A (es) Composiciones para el cuidado personal.
MX2022014634A (es) Metodos para la administracion linfatica de agentes activos.
MX2017016774A (es) Agente terapeutico para la fibrosis.
MX395112B (es) Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial.
MX2022014577A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
ECSP13012988A (es) Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
MX2021002444A (es) Compuestos y metodos para el tratamiento de infecciones fungicas.
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
CL2018002200A1 (es) Administración combinada de un agente de penetración y un compuesto de azufre que contiene compuesto para las plantas.
MX389461B (es) Composiciones que comprenden una matriz de polisacarido para la liberacion controlada de ingredientes activos
MX2016009567A (es) Composicion antifungica.
DOP2016000213A (es) Composición antifúngica tópica para el tratamiento de onicomicosis